A MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2 STUDY OF THE EFFICACY, SAFETY AND TOLERABILITY OF RG1662 IN ADULTS AND ADOLESCENTS WITH DOWN SYNDROME (CLEMATIS)

Trial Profile

A MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2 STUDY OF THE EFFICACY, SAFETY AND TOLERABILITY OF RG1662 IN ADULTS AND ADOLESCENTS WITH DOWN SYNDROME (CLEMATIS)

Completed
Phase of Trial: Phase II

Latest Information Update: 21 Mar 2017

At a glance

  • Drugs Basmisanil (Primary)
  • Indications Down syndrome
  • Focus Therapeutic Use
  • Acronyms CLEMATIS
  • Sponsors Roche
  • Most Recent Events

    • 01 Jul 2016 Status changed from recruiting to completed.
    • 27 Jun 2016 This trial was completed in Spain (end date: 06-05-2016), according to European Clinical Trials Database.
    • 04 Apr 2016 Status changed from active, no longer recruiting to recruiting as reported by Clinicaltrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top